Drug Shortage Scrutiny: GAO Plans Study Of FDA’s Expedited Applications
Government watchdog wants to look at how the agency expedites applications that could help alleviate a shortage, but cautions that process alone cannot reduce shortages.
You may also be interested in...
GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.
House hearing includes arguments that regulatory delays thwart the market’s response to shortage price signals, suggesting reforms could be included in user fee legislation along with the popular early warning requirement.
In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.